Search
Cefaloridine
go.drugbank.com/drugs/DB09008ApprovedWithdrawnCephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.
Alatrofloxacin
go.drugbank.com/drugs/DB09335ApprovedWithdrawnAlatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and...
NV-07a
go.drugbank.com/drugs/DB05845ExperimentalNV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Brifentanil
go.drugbank.com/drugs/DB09172ExperimentalIllicitBrifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.
Fexapotide
go.drugbank.com/drugs/DB05493InvestigationalNX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.
Rosin
go.drugbank.com/drugs/DB11165ApprovedIn the pharmaceuticals, rosin is used in film forming and coating tablets and enterically administered agents, as well as forming microcapsules and nanoparticles. … Rosin is a solid form of resin obtained from pines and other plants, mostly conifers. It is prepared from heating fresh liquid resin to vaporize the volatile liquid terpene components.
Categories: Compounds used in a research, industrial, or household settingEnmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigationalEnmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. … [L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalAmrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer
Deudextromethorphan
go.drugbank.com/drugs/DB19054InvestigationalDeudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an